The role of oxidative stress in the pathogenesis of Graves’ orbitopathy

[1] Abraham-Nordling M., Byström K., Törring O., Lantz M., Berg G., Calissendorff J., Nyström H.F., Jansson S., Jörneskog G., Karlsson F.A., Nyström E., Ohrling H., Orn T., Hallengren B., Wallin G.: Incidence of hyperthyroidism in Sweden. Eur. J. Endocrinol., 2011; 165: 899–905 Abraham-NordlingM. ByströmK. TörringO. LantzM. BergG. CalissendorffJ. NyströmH.F. JanssonS. JörneskogG. KarlssonF.A. NyströmE. OhrlingH. OrnT. HallengrenB. WallinG. Incidence of hyperthyroidism in Sweden Eur. J. Endocrinol. 2011 165 899 905 10.1530/EJE-11-054821908653 Search in Google Scholar

[2] Akarsu E., Buyukhatipoglu H., Aktaran S., Kurtul N.: Effects of pulse methyloprednisolone and oral methyloprednisolone treatments on serum levels of oxidative stress markers in Graves’ ophthalmopathy. Clin. Endocrinol., 2011; 74: 118–124 AkarsuE. BuyukhatipogluH. AktaranS. KurtulN. Effects of pulse methyloprednisolone and oral methyloprednisolone treatments on serum levels of oxidative stress markers in Graves’ ophthalmopathy Clin. Endocrinol. 2011 74 118 124 10.1111/j.1365-2265.2010.03904.x21044110 Search in Google Scholar

[3] Ames B.N., Cathcart R., Schwiers E., Hochstein P.: Uric acid provides an antioxidant defense in humans against oxidant and radical-caused aging and cancer: A hypothesis. Proc. Natl. Acad. Sci. USA, 1981; 78: 6858–6862 AmesB.N. CathcartR. SchwiersE. HochsteinP. Uric acid provides an antioxidant defense in humans against oxidant and radical-caused aging and cancer: A hypothesis Proc. Natl. Acad. Sci. USA 1981 78 6858 6862 10.1073/pnas.78.11.68583491516947260 Search in Google Scholar

[4] Azizi F., Raiszadeh F., Solati M., Etemadi A., Rahmani M., Arabi M.: Serum paraoxonase 1 activity is decreased in thyroid dysfunction. J. Endocrinol. Invest., 2003; 26: 703–709 AziziF. RaiszadehF. SolatiM. EtemadiA. RahmaniM. ArabiM. Serum paraoxonase 1 activity is decreased in thyroid dysfunction J. Endocrinol. Invest. 2003 26 703 709 10.1007/BF0334735014669822 Search in Google Scholar

[5] Barnes P.J.: Anti-inflammatory actions of glucocorticoids: Molecular mechanisms. Clin. Sci., 1998; 94: 557–572 BarnesP.J. Anti-inflammatory actions of glucocorticoids: Molecular mechanisms Clin. Sci. 1998 94 557 572 10.1042/cs09405579854452 Search in Google Scholar

[6] Bartalena L., Baldeschi L., Boboridis K., Eckstein A., Kahaly G.J., Marcocci C., Perros P., Salvi M., Wiersinga W.M., European Group on Graves’ Orbitopathy (EUGOGO): The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy guidelines for the management of Graves’ orbitopathy. Eur. Thyroid J., 2016; 5: 9–26 BartalenaL. BaldeschiL. BoboridisK. EcksteinA. KahalyG.J. MarcocciC. PerrosP. SalviM. WiersingaW.M. European Group on Graves’ Orbitopathy (EUGOGO) The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy guidelines for the management of Graves’ orbitopathy Eur. Thyroid J. 2016 5 9 26 10.1159/000443828483612027099835 Search in Google Scholar

[7] Bartalena L., Piantanida E.: Cigarette smoking: Number one enemy for Graves’ ophthalmopathy. Pol. Arch. Med. Wewn., 2016; 126: 725–726 BartalenaL. PiantanidaE. Cigarette smoking: Number one enemy for Graves’ ophthalmopathy Pol. Arch. Med. Wewn. 2016 126 725 726 10.20452/pamw.359227872448 Search in Google Scholar

[8] Bartalena L., Tanda M.L.: Clinical practice. Graves’ ophthalmopathy. N. Engl. J. Med., 2009; 360: 994–1001 BartalenaL. TandaM.L. Clinical practice. Graves’ ophthalmopathy N. Engl. J. Med. 2009 360 994 1001 10.1056/NEJMcp080631719264688 Search in Google Scholar

[9] Bartelena L., Tanda M.L., Piantanida E., Lai A.: Oxidative stress Graves’ ophthalmopathy: In vitro studies and therapeutic implications. Biofactors, 2003; 19: 155–163 BartelenaL. TandaM.L. PiantanidaE. LaiA. Oxidative stress Graves’ ophthalmopathy: In vitro studies and therapeutic implications Biofactors 2003 19 155 163 10.1002/biof.552019030814757966 Search in Google Scholar

[10] Başkol G., Dolbun Seçkin K., Bayram F., Tanriverdi F.: Investigation of serum paraoxonase -1 activity and lipid levels in patients with hyperthyroidism. Turk. J. Med. Sci., 2012; 42: 1166–1171 BaşkolG. Dolbun SeçkinK. BayramF. TanriverdiF. Investigation of serum paraoxonase -1 activity and lipid levels in patients with hyperthyroidism Turk. J. Med. Sci. 2012 42 1166 1171 10.3906/sag-1202-87 Search in Google Scholar

[11] Bednarek J., Wysocki H., Sowiński J.: Oxidative stress peripheral parameters in Graves’ disease: The effect of methimazole treatment in patients with and without infiltrative ophthalmopathy. Clin. Biochem., 2005; 38: 13–18 BednarekJ. WysockiH. SowińskiJ. Oxidative stress peripheral parameters in Graves’ disease: The effect of methimazole treatment in patients with and without infiltrative ophthalmopathy Clin. Biochem. 2005 38 13 18 10.1016/j.clinbiochem.2004.09.01515607311 Search in Google Scholar

[12] Bednarek J., Wysocki H., Sowiński J.: Peripheral parameters of oxidative stress in patients with infiltrative Graves’ ophtalmopathy treated with corticosteroids. Immunol. Lett., 2004; 93: 227–232 BednarekJ. WysockiH. SowińskiJ. Peripheral parameters of oxidative stress in patients with infiltrative Graves’ ophtalmopathy treated with corticosteroids Immunol. Lett. 2004 93 227 232 10.1016/j.imlet.2004.03.020 Search in Google Scholar

[13] Bednarek J., Wysocki H., Sowinski J.: Oxidation products and antioxidant markers in plasma of patients with Graves’ disease and toxic multinodular goiter: Effect of methimazole treatment. Free Radic. Res., 2004; 38: 659–664 BednarekJ. WysockiH. SowinskiJ. Oxidation products and antioxidant markers in plasma of patients with Graves’ disease and toxic multinodular goiter: Effect of methimazole treatment Free Radic. Res. 2004 38 659 664 10.1080/10715760410001701621 Search in Google Scholar

[14] Bianchi G., Solaroli E., Zaccheroni V., Grossi G., Bargossi A.M., Melchionda N., Marchesini G.: Oxidative stress and anti-oxidant metabolites in patients with hyperthyroidism: Effect of treatment. Horm. Metab. Res., 1999; 31: 620–624 BianchiG. SolaroliE. ZaccheroniV. GrossiG. BargossiA.M. MelchiondaN. MarchesiniG. Oxidative stress and anti-oxidant metabolites in patients with hyperthyroidism: Effect of treatment Horm. Metab. Res. 1999 31 620 624 10.1055/s-2007-978808 Search in Google Scholar

[15] Blair I.A.: Lipid hydroperoxide-mediated DNA damage. Exp. Gerontol., 2001; 36: 1473–1481 BlairI.A. Lipid hydroperoxide-mediated DNA damage Exp. Gerontol. 2001 36 1473 1481 10.1016/S0531-5565(01)00133-4 Search in Google Scholar

[16] Botta R., Lisi S., Marcocci C., Sellari-Franceschini S., Rocchi R., Latrofa F., Menconi F., Altea M.A., Leo M., Sisti E., Casini G., Nardi M., Pinchera A., Vitti P., Marinò M.: Enalapril reduces proliferation and hyaluronic acid release in orbital fibroblasts. Thyroid, 2013; 23: 92–96 BottaR. LisiS. MarcocciC. Sellari-FranceschiniS. RocchiR. LatrofaF. MenconiF. AlteaM.A. LeoM. SistiE. CasiniG. NardiM. PincheraA. VittiP. MarinòM. Enalapril reduces proliferation and hyaluronic acid release in orbital fibroblasts Thyroid 2013 23 92 96 10.1089/thy.2012.0373 Search in Google Scholar

[17] Bouzas E.A., Karadimas P, Mastorakos G., Koutras D.A.: Anti-oxidant agents in the treatment of Graves’ opthalmopathy. Am. J. Ophthalmol., 2000; 129: 618–622 BouzasE.A. KaradimasP MastorakosG. KoutrasD.A. Anti-oxidant agents in the treatment of Graves’ opthalmopathy Am. J. Ophthalmol. 2000 129 618 622 10.1016/S0002-9394(00)00359-7 Search in Google Scholar

[18] Burch H.B., Lahiri S., Bahn R.S., Barnes S.: Superoxide radical production stimulates retroocular fibroblast proliferation in Graves’ ophthalmopathy. Exp. Eye Res., 1997; 65: 311–316 BurchH.B. LahiriS. BahnR.S. BarnesS. Superoxide radical production stimulates retroocular fibroblast proliferation in Graves’ ophthalmopathy Exp. Eye Res. 1997 65 311 316 10.1006/exer.1997.03539268599 Search in Google Scholar

[19] Cawood T.J., Moriarty P., O’Farrelly C., O’Shea D.: Smoking and thyroid-associated ophthalmopathy: A novel explanation of the biological link. J. Clin. Endocrinol. Metab., 2007; 92: 59–64 CawoodT.J. MoriartyP. O’FarrellyC. O’SheaD. Smoking and thyroid-associated ophthalmopathy: A novel explanation of the biological link J. Clin. Endocrinol. Metab. 2007 92 59 64 10.1210/jc.2006-182417047020 Search in Google Scholar

[20] Choi W., Li Y., Ji Y.S., Yoon K.C.: Oxidative stress markers in tears of patients with Graves’ orbitopathy and their correlation with clinical activity score. BMC Ophthalmol., 2018; 18: 303 ChoiW. LiY. JiY.S. YoonK.C. Oxidative stress markers in tears of patients with Graves’ orbitopathy and their correlation with clinical activity score BMC Ophthalmol. 2018 18 303 10.1186/s12886-018-0969-x624997130463536 Search in Google Scholar

[21] Dong Y.H., Fu D.G.: Autoimmune thyroid disease: Mechanism, genetics and current knowledge. Eur. Rev. Med. Pharmacol. Sci., 2014; 18: 3611–3618 DongY.H. FuD.G. Autoimmune thyroid disease: Mechanism, genetics and current knowledge Eur. Rev. Med. Pharmacol. Sci. 2014 18 3611 3618 Search in Google Scholar

[22] Duntas L.H.: Selenium and the thyroid: A close-knit connection. J. Clin. Endocrinol. Metab., 2010; 95: 5180–5188 DuntasL.H. Selenium and the thyroid: A close-knit connection J. Clin. Endocrinol. Metab. 2010 95 5180 5188 10.1210/jc.2010-019120810577 Search in Google Scholar

[23] Effraimidis G., Wiersinga W.M.: Mechanisms in endocrinology: Autoimmune thyroid disease: Old and new players. Eur. J. Endocrinol., 2014; 170: R241–R252 EffraimidisG. WiersingaW.M. Mechanisms in endocrinology: Autoimmune thyroid disease: Old and new players Eur. J. Endocrinol. 2014 170 R241 R252 10.1530/EJE-14-0047 Search in Google Scholar

[24] Gianoukakis A.G., Khadavi N., Smith T.J.: Cytokines, Graves’ disease, and thyroid-associated ophthalmopathy. Thyroid, 2008; 18: 953–958 GianoukakisA.G. KhadaviN. SmithT.J. Cytokines, Graves’ disease, and thyroid-associated ophthalmopathy Thyroid 2008 18 953 958 10.1089/thy.2007.0405 Search in Google Scholar

[25] Haddad J.J.: Oxygen sensing and oxidant/redox-related pathways. Biochem. Biophys. Res. Commun., 2004; 316: 969–977 HaddadJ.J. Oxygen sensing and oxidant/redox-related pathways Biochem. Biophys. Res. Commun. 2004 316 969 977 10.1016/j.bbrc.2004.02.162 Search in Google Scholar

[26] Halliwell B., Gulleridge J.M.: Oxygen radicals and the nervous system. Trends Neurosci., 1985; 8: 22–26 HalliwellB. GulleridgeJ.M. Oxygen radicals and the nervous system Trends Neurosci. 1985 8 22 26 10.1016/0166-2236(85)90010-4 Search in Google Scholar

[27] Hardeland R., Pandi-Perumal S.R., Cardinali D.P.: Melatonin. Int. J. Biochem. Cell. Biol., 2006; 38: 313–316 HardelandR. Pandi-PerumalS.R. CardinaliD.P. Melatonin Int. J. Biochem. Cell. Biol. 2006 38 313 316 10.1016/B978-0-12-801238-3.62140-2 Search in Google Scholar

[28] Heufelder A.E., Wenzel B.E., Bahn R.S.: Methimazole and propylthiouracil inhibit the oxygen free radical-induced expression of a 72 kilodalton heat shock protein in Graves’ retroocular fibroblasts. J. Clin. Endocrinol. Metab., 1992; 74: 737–742 HeufelderA.E. WenzelB.E. BahnR.S. Methimazole and propylthiouracil inhibit the oxygen free radical-induced expression of a 72 kilodalton heat shock protein in Graves’ retroocular fibroblasts J. Clin. Endocrinol. Metab. 1992 74 737 742 10.1210/jcem.74.4.15321791532179 Search in Google Scholar

[29] Heufelder A.E., Wenzel B.E., Bahn R.S.: Cell surface localization of a 72 kilodalton heat shock protein in retroocular fibroblasts from patients with Graves’ ophthalmopathy. J. Clin. Endocrinol. Metab., 1992; 74: 732–736 HeufelderA.E. WenzelB.E. BahnR.S. Cell surface localization of a 72 kilodalton heat shock protein in retroocular fibroblasts from patients with Graves’ ophthalmopathy J. Clin. Endocrinol. Metab. 1992 74 732 736 10.1210/jcem.74.4.15483351548335 Search in Google Scholar

[30] Hondur A., Konuk O., Dincel A.S., Bilgihan A., Unal M., Hasanreisoglu B.: Oxidative stress and antioxidant activity in orbital fibroadipose tissue in Graves’ ophthalmopathy. Curr. Eye Res., 2008; 33: 421–427 HondurA. KonukO. DincelA.S. BilgihanA. UnalM. HasanreisogluB. Oxidative stress and antioxidant activity in orbital fibroadipose tissue in Graves’ ophthalmopathy Curr. Eye Res. 2008 33 421 427 10.1080/0271368080212353218568878 Search in Google Scholar

[31] Iyer S., Bahn R.: Immunopathogenesis of Graves’ ophthalmopathy: The role of the TSH receptor. Best. Pract. Res. Clin. Endocrinol. Metab., 2012; 26: 281–289 IyerS. BahnR. Immunopathogenesis of Graves’ ophthalmopathy: The role of the TSH receptor Best. Pract. Res. Clin. Endocrinol. Metab. 2012 26 281 289 10.1016/j.beem.2011.10.003336167922632365 Search in Google Scholar

[32] Karasek D., Cibickova L., Karhanova M., Kalitova J., Schovanek J., Frysak Z.: Clinical and immunological changes in patients with active moderate-to-severe Graves’ orbitopathy treated with very low-dose rituximab. Endokrynol. Pol., 2017; 68: 498–504 KarasekD. CibickovaL. KarhanovaM. KalitovaJ. SchovanekJ. FrysakZ. Clinical and immunological changes in patients with active moderate-to-severe Graves’ orbitopathy treated with very low-dose rituximab Endokrynol. Pol. 2017 68 498 504 Search in Google Scholar

[33] Karbownik M., Lewinski A.: The role of oxidative stress in physiological and pathological processes in the thyroid gland; possible involvement in pineal-thyroid interactions. Neuro Endocrinol. Lett., 2003; 24: 293–303 KarbownikM. LewinskiA. The role of oxidative stress in physiological and pathological processes in the thyroid gland; possible involvement in pineal-thyroid interactions Neuro Endocrinol. Lett. 2003 24 293 303 Search in Google Scholar

[34] Karihtala P., Kauppila S., Puistola U., Jukkola-Vuorinen A.: Divergent behaviour of oxidative stress markers 8-hydroxydeoxyguanosine (8-OHdG) and 4-hydroxy-2-nonenal (HNE) in breast carcinogenesis. Histopathology, 2011; 58: 854–862 KarihtalaP. KauppilaS. PuistolaU. Jukkola-VuorinenA. Divergent behaviour of oxidative stress markers 8-hydroxydeoxyguanosine (8-OHdG) and 4-hydroxy-2-nonenal (HNE) in breast carcinogenesis Histopathology 2011 58 854 862 10.1111/j.1365-2559.2011.03835.x21585424 Search in Google Scholar

[35] Khalilzadeh O., Anvari M., Momen-Heravi F., Esteghamati A., Rashidi A., Mahmoudi M., Nikbin B., Amirzargar A.: Gene polymorphisms of interleukin-4, interleukin-10 and transforming growth factor-beta in Graves’ disease. Clin. Exp. Med., 2010; 10: 123–128 KhalilzadehO. AnvariM. Momen-HeraviF. EsteghamatiA. RashidiA. MahmoudiM. NikbinB. AmirzargarA. Gene polymorphisms of interleukin-4, interleukin-10 and transforming growth factor-beta in Graves’ disease Clin. Exp. Med. 2010 10 123 128 10.1007/s10238-009-0078-5 Search in Google Scholar

[36] Khong J.J., McNab A.A., Ebeling P.R., Craig J.E., Selva D.: Pathogenesis of thyroid eye disease: Review and update on molecular mechanisms. Br. J. Ophthalmol., 2016; 100: 142–150 KhongJ.J. McNabA.A. EbelingP.R. CraigJ.E. SelvaD. Pathogenesis of thyroid eye disease: Review and update on molecular mechanisms Br. J. Ophthalmol. 2016 100 142 150 10.1136/bjophthalmol-2015-307399 Search in Google Scholar

[37] Komosinska-Vassev K., Olczyk K., Kucharz E.J., Marcisz C., Winsz-Szczotka K., Kotulska A.: Free radical activity and antioxidant defense mechanisms in patients with hyperthyroidism due to Graves’ disease during therapy. Clin. Chim. Acta, 2000; 300: 107–117 Komosinska-VassevK. OlczykK. KucharzE.J. MarciszC. Winsz-SzczotkaK. KotulskaA. Free radical activity and antioxidant defense mechanisms in patients with hyperthyroidism due to Graves’ disease during therapy Clin. Chim. Acta 2000 300 107 117 10.1016/S0009-8981(00)00306-5 Search in Google Scholar

[38] Kucharzewski M., Braziewicz J., Majewska U., Góźdź S.: Concentration of selenium in the whole blood and the thyroid tissue of patients with various thyroid diseases. Biol. Trace Elem. Res., 2002; 88: 25–30 KucharzewskiM. BraziewiczJ. MajewskaU. GóźdźS. Concentration of selenium in the whole blood and the thyroid tissue of patients with various thyroid diseases Biol. Trace Elem. Res. 2002 88 25 30 10.1385/BTER:88:1:25 Search in Google Scholar

[39] Laurberg P., Berman D.C., Bülow Pedersen I., Andersen S., Carlé A.: Incidence and clinical presentation of moderate to severe Graves’ orbitopathy in a Danish population before and after iodine fortification of salt. J. Clin. Endocrinol. Metab., 2012; 97: 2325–2332 LaurbergP. BermanD.C. Bülow PedersenI. AndersenS. CarléA. Incidence and clinical presentation of moderate to severe Graves’ orbitopathy in a Danish population before and after iodine fortification of salt J. Clin. Endocrinol. Metab. 2012 97 2325 2332 10.1210/jc.2012-1275 Search in Google Scholar

[40] Levine M.: New concepts in the biology and biochemistry of ascorbic acid. N. Engl. J. Med., 1986; 314: 892–902 LevineM. New concepts in the biology and biochemistry of ascorbic acid N. Engl. J. Med. 1986 314 892 902 10.3109/13590849208997993 Search in Google Scholar

[41] Lindquist S.: The heat-shock response. Ann. Rev. Biochem., 1986; 55: 1151–1191 LindquistS. The heat-shock response Ann. Rev. Biochem. 1986 55 1151 1191 10.1146/annurev.bi.55.070186.005443 Search in Google Scholar

[42] Lisi S., Botta R., Lemmi M., Sellari-Franceschini S., Altea M.A., Sisti E., Casini G., Nardi M., Marcocci C., Pinchera A., Marinò M.: Quercetin decreases proliferation of orbital fibroblasts and their release of hyaluronic acid. J. Endocrinol. Invest., 2011; 34: 521–527 LisiS. BottaR. LemmiM. Sellari-FranceschiniS. AlteaM.A. SistiE. CasiniG. NardiM. MarcocciC. PincheraA. MarinòM. Quercetin decreases proliferation of orbital fibroblasts and their release of hyaluronic acid J. Endocrinol. Invest. 2011 34 521 527 Search in Google Scholar

[43] Liu X., Zhang J., Meng Z., Jia Q., Tan J., Zhang G., Li X., Liu N., Hu T., Zhou P., Zhang Q., Song K., Jia Q.: Gender impact on the correlations between Graves’ hyperthyroidism and hyperuricemia in Chinese. Ir. J. Med. Sci., 2019; 188: 843–848 LiuX. ZhangJ. MengZ. JiaQ. TanJ. ZhangG. LiX. LiuN. HuT. ZhouP. ZhangQ. SongK. JiaQ. Gender impact on the correlations between Graves’ hyperthyroidism and hyperuricemia in Chinese Ir. J. Med. Sci. 2019 188 843 848 10.1007/s11845-018-1939-2 Search in Google Scholar

[44] Marcocci C., Altea M.A., Kahaly G., Pitz S., Krassas G., Boboridia K., Bartalena L., Sivelli M., von Arx G., Stahl M., Nardi M., Mourits M., Baldeschi L., Pinchera A., Wiersinga W. I wsp.: Selenium and pentoxifylline in patients with mild Graves’ orbitopathy: Results of a randomized placebo-controlled double-blind clinical trial. Endocr. Abstr., 2010; 22: P866 MarcocciC. AlteaM.A. KahalyG. PitzS. KrassasG. BoboridiaK. BartalenaL. SivelliM. von ArxG. StahlM. NardiM. MouritsM. BaldeschiL. PincheraA. WiersingaW. Selenium and pentoxifylline in patients with mild Graves’ orbitopathy: Results of a randomized placebo-controlled double-blind clinical trial Endocr. Abstr. 2010 22 P866 Search in Google Scholar

[45] Marcocci C., Bartalena L.: Role of oxidative stress and selenium in Graves’ hyperthyroidism and orbitopathy. J. Endocrinol. Investig., 2013; 36: 15–20 MarcocciC. BartalenaL. Role of oxidative stress and selenium in Graves’ hyperthyroidism and orbitopathy J. Endocrinol. Investig. 2013 36 15 20 Search in Google Scholar

[46] Marcocci C., Kahaly G.J., Krassas G.E., Bartalena L., Prummel M., Stahl M., Altea M.A., Nardi M., Pitz S., Boboridis K., Sivelli P., von Arx G., Mourits M.P., Baldeschi L., Bencivelli W. i wsp.: Selenium and the course of mild Graves’ orbitopathy. N. Engl. J. Med., 2011; 364: 1920–1931 MarcocciC. KahalyG.J. KrassasG.E. BartalenaL. PrummelM. StahlM. AlteaM.A. NardiM. PitzS. BoboridisK. SivelliP. von ArxG. MouritsM.P. BaldeschiL. BencivelliW. Selenium and the course of mild Graves’ orbitopathy N. Engl. J. Med. 2011 364 1920 1931 10.1056/NEJMoa1012985 Search in Google Scholar

[47] Marinò M., Chiovato L., Lisi S., Altea M.A., Marcocci C., Pinchera A.: Role of thyroglobulin in the pathogenesis of Graves’ ophthalmopathy: The hypothesis of Kriss revisited. J. Endocrinol. Invest., 2004; 27: 230–236 MarinòM. ChiovatoL. LisiS. AlteaM.A. MarcocciC. PincheraA. Role of thyroglobulin in the pathogenesis of Graves’ ophthalmopathy: The hypothesis of Kriss revisited J. Endocrinol. Invest. 2004 27 230 236 10.1007/BF03345271 Search in Google Scholar

[48] Marnett L.J.: Oxy radicals, lipid peroxidation and DNA damage. Toxicology, 2002; 181–182: 219–222 MarnettL.J. Oxy radicals, lipid peroxidation and DNA damage Toxicology 2002 181–182 219 222 10.1016/S0300-483X(02)00448-1 Search in Google Scholar

[49] Mayer L., Romić Z., Skreb F., Bacić-Vrca V., Cepelak I., Zanić-Grubisić T., Kirin M.: Antioxidants in patients with hyperthyroidism. Clin. Chem. Lab. Med., 2004; 42: 154–158 MayerL. RomićZ. SkrebF. Bacić-VrcaV. CepelakI. Zanić-GrubisićT. KirinM. Antioxidants in patients with hyperthyroidism Clin. Chem. Lab. Med. 2004 42 154 158 10.1515/CCLM.2004.02815061353 Search in Google Scholar

[50] Mezosi E., Szabo J., Nagy E.V., Borbely A., Varga E., Paragh G., Varga Z.: Nongenomic effect of thyroid hormone on free-radical production in human polymorphonuclear leukocytes. J. Endcorinol., 2005; 185: 121–129 MezosiE. SzaboJ. NagyE.V. BorbelyA. VargaE. ParaghG. VargaZ. Nongenomic effect of thyroid hormone on free-radical production in human polymorphonuclear leukocytes J. Endcorinol. 2005 185 121 129 10.1677/joe.1.0596815817833 Search in Google Scholar

[51] Mikozami T., Salvi M., Wall J.R.: Eye muscle antibodies in Graves’ ophthalmopathy: Pathogenic or secondary epiphenomenon? J. Endocrinol. Invest., 2004; 27: 221–229 MikozamiT. SalviM. WallJ.R. Eye muscle antibodies in Graves’ ophthalmopathy: Pathogenic or secondary epiphenomenon? J. Endocrinol. Invest. 2004 27 221 229 10.1007/BF0334527015164997 Search in Google Scholar

[52] Murrell G.A., Francis M.J., Bromley L.: Modulation of fibro-blast proliferation by oxygen free radicals. Biochem. J., 1990; 265: 659–665 MurrellG.A. FrancisM.J. BromleyL. Modulation of fibro-blast proliferation by oxygen free radicals Biochem. J. 1990 265 659 665 10.1042/bj265065911336852154966 Search in Google Scholar

[53] Myśliwiec J., Palyga I., Nikolajuk A., Kowalska A., Gorska M.: Serum interleukin-16 and RANTES during treatment of Graves’ orbitopathy with corticosteroids and teleradiotherapy. Endokrynol. Pol., 2012; 63: 92–96 MyśliwiecJ. PalygaI. NikolajukA. KowalskaA. GorskaM. Serum interleukin-16 and RANTES during treatment of Graves’ orbitopathy with corticosteroids and teleradiotherapy Endokrynol. Pol. 2012 63 92 96 Search in Google Scholar

[54] Niedernhofer L.J., Daniels J.S., Rouzer C.A., Greene R.E., Marnett L.J.: Malondialdehyde, a product of lipid peroxidation, is mutagenic in human cells. J. Biol. Chem., 2003; 278: 31426–31433 NiedernhoferL.J. DanielsJ.S. RouzerC.A. GreeneR.E. MarnettL.J. Malondialdehyde, a product of lipid peroxidation, is mutagenic in human cells J. Biol. Chem. 2003 278 31426 31433 10.1074/jbc.M21254920012775726 Search in Google Scholar

[55] Nowak M., Marek B., Karpe J., Kos-Kudła B., Siemińska L., Kajdaniuk D., Treszer T.: Serum concentration of VEGF and PDGF-AA in patients with active thyroid orbitopathy before and after immunosuppressive therapy. Exp. Clin. Endocrinol. Diabetes, 2014; 122: 582–586 NowakM. MarekB. KarpeJ. Kos-KudłaB. SiemińskaL. KajdaniukD. TreszerT. Serum concentration of VEGF and PDGF-AA in patients with active thyroid orbitopathy before and after immunosuppressive therapy Exp. Clin. Endocrinol. Diabetes 2014 122 582 586 10.1055/s-0034-138357925140996 Search in Google Scholar

[56] Nowak M., Siemińska L., Karpe J., Marek B., Kos-Kudła B., Kajdaniuk D.: Serum concentrations of HGF and IL-8 in patients with active Graves’ orbitopathy before and after methylprednisolone therapy. J. Endocrinol. Invest., 2016; 39: 63–72 NowakM. SiemińskaL. KarpeJ. MarekB. Kos-KudłaB. KajdaniukD. Serum concentrations of HGF and IL-8 in patients with active Graves’ orbitopathy before and after methylprednisolone therapy J. Endocrinol. Invest. 2016 39 63 72 10.1007/s40618-015-0322-7470360726062519 Search in Google Scholar

[57] Puzanowska-Tarasiewicz H., Starczewska B., Kuźmicka L.: Reaktywne formy tlenu. Bromat. Chem. Toksykol., 2008; 41: 1007–1015 Puzanowska-TarasiewiczH. StarczewskaB. KuźmickaL. Reaktywne formy tlenu Bromat. Chem. Toksykol. 2008 41 1007 1015 Search in Google Scholar

[58] Raiszadeh F., Solati M., Etemadi A., Azizi F.: Serum paraoxonase activity before and after treatment of thyrotoxicosis. Clin. Endocrinol., 2004; 60: 75–80 RaiszadehF. SolatiM. EtemadiA. AziziF. Serum paraoxonase activity before and after treatment of thyrotoxicosis Clin. Endocrinol. 2004 60 75 80 10.1111/j.1365-2265.2004.01940.x14678291 Search in Google Scholar

[59] Rajkovic M.G., Rumora L., Barisic K.: The paraoxonase 1, 2 and 3 in humans. Biochem. Med., 2011; 21: 122–130 RajkovicM.G. RumoraL. BarisicK. The paraoxonase 1, 2 and 3 in humans Biochem. Med. 2011 21 122 130 10.11613/BM.2011.02022135851 Search in Google Scholar

[60] Resch U., Helsel G., Tatzber F., Sinzinger H.: Antioxidant status in thyroid dysfunction. Clin. Chem. Lab. Med., 2002; 40: 1132–1134 ReschU. HelselG. TatzberF. SinzingerH. Antioxidant status in thyroid dysfunction Clin. Chem. Lab. Med. 2002 40 1132 1134 10.1515/cclm.2002.198 Search in Google Scholar

[61] Rotondo Dottore G., Ionni I., Menconi F., Casini G., Sellari-Franceschini S., Nardi M., Vitti P., Marcocci C., Marinò M.: Action of three bioavailable antioxidants in orbital fibroblasts from patients with Graves’ orbitopathy (GO): A new frontier for GO treatment? J. Endocrinol. Invest., 2018; 41: 193–201 Rotondo DottoreG. IonniI. MenconiF. CasiniG. Sellari-FranceschiniS. NardiM. VittiP. MarcocciC. MarinòM. Action of three bioavailable antioxidants in orbital fibroblasts from patients with Graves’ orbitopathy (GO): A new frontier for GO treatment? J. Endocrinol. Invest. 2018 41 193 201 10.1007/s40618-017-0718-7 Search in Google Scholar

[62] Rotondo Dottore G., Ionni I., Menconi F., Casini G., Sellari-Franceschini S., Nardi M., Vitti P., Marcocci C., Marinò M.: Antioxidant effects of β-carotene, but not of retinol and Vitamin E, in orbital fibroblasts from patients with Graves’ orbitopathy (GO). J. Endocrinol. Invest., 2018; 41: 815–820 Rotondo DottoreG. IonniI. MenconiF. CasiniG. Sellari-FranceschiniS. NardiM. VittiP. MarcocciC. MarinòM. Antioxidant effects of β-carotene, but not of retinol and Vitamin E, in orbital fibroblasts from patients with Graves’ orbitopathy (GO) J. Endocrinol. Invest. 2018 41 815 820 10.1007/s40618-017-0809-5 Search in Google Scholar

[63] Rotondo Dottore G., Leo M., Casini G., Latrofa F., Cestari L., Sellari-Franceschini S., Nardi M., Vitti P., Marcocci C., Marinò M.: Antioxidant actions of selenium in orbital fibroblasts: A basis for the effects of selenium in Graves’ orbitopathy. Thyroid, 2017; 27: 271–278 Rotondo DottoreG. LeoM. CasiniG. LatrofaF. CestariL. Sellari-FranceschiniS. NardiM. VittiP. MarcocciC. MarinòM. Antioxidant actions of selenium in orbital fibroblasts: A basis for the effects of selenium in Graves’ orbitopathy Thyroid 2017 27 271 278 10.1089/thy.2016.0397 Search in Google Scholar

[64] Russell D.J., Wagner L.H., Seiff S.R.: Tocilizumab as a steroid sparing agent for the treatment of Graves’ orbitopathy. Am. J. Ophthalmol. Case Rep., 2017; 7: 146–148 RussellD.J. WagnerL.H. SeiffS.R. Tocilizumab as a steroid sparing agent for the treatment of Graves’ orbitopathy Am. J. Ophthalmol. Case Rep. 2017 7 146 148 10.1016/j.ajoc.2017.07.001 Search in Google Scholar

[65] Sadani G.R., Nadkarni G.D.: Role of tissue antioxidant defence in thyroid cancers. Cancer Lett., 1996; 109: 231–235 SadaniG.R. NadkarniG.D. Role of tissue antioxidant defence in thyroid cancers Cancer Lett. 1996 109 231 235 10.1016/S0304-3835(96)04484-9 Search in Google Scholar

[66] Salvi M., Vannucchi G., Currò N., Campi I., Covelli D., Dazzi D., Simonetta S., Guastella C., Pignataro L., Avignone S, Beck-Peccoz P.: Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves’ orbitopathy: A randomized controlled study. J. Clin. Endocrinol. Metab., 2015; 100: 422–431 SalviM. VannucchiG. CurròN. CampiI. CovelliD. DazziD. SimonettaS. GuastellaC. PignataroL. AvignoneS Beck-PeccozP. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves’ orbitopathy: A randomized controlled study J. Clin. Endocrinol. Metab. 2015 100 422 431 10.1210/jc.2014-3014 Search in Google Scholar

[67] Sato A., Shirota T., Shinoda T., Komiya I., Aizawa T., Takemura Y., Yamada T.: Hyperuricemia in patients with hyperthyroidism due to Graves’ disease. Metabolism, 1995; 44: 207–211 SatoA. ShirotaT. ShinodaT. KomiyaI. AizawaT. TakemuraY. YamadaT. Hyperuricemia in patients with hyperthyroidism due to Graves’ disease Metabolism 1995 44 207 211 10.1016/0026-0495(95)90266-X Search in Google Scholar

[68] Schomburg L., Köhrle J.: On the importance of selenium and iodine metabolism for thyroid hormone biosynthesis and human health. Mol. Nutr. Food Res., 2008; 52: 1235–1246 SchomburgL. KöhrleJ. On the importance of selenium and iodine metabolism for thyroid hormone biosynthesis and human health Mol. Nutr. Food Res. 2008 52 1235 1246 10.1002/mnfr.20070046518686295 Search in Google Scholar

[69] Seven A., Taşan E., Inci F., Hatemi H., Burçak G.: Biochemical evaluation of oxidative stress in propylthiouracil treated hyperthyroid patients. Effects of vitamin C supplementation. Clin. Chem. Lab. Med., 1998; 36: 767–770 SevenA. TaşanE. InciF. HatemiH. BurçakG. Biochemical evaluation of oxidative stress in propylthiouracil treated hyperthyroid patients. Effects of vitamin C supplementation Clin. Chem. Lab. Med. 1998 36 767 770 10.1515/CCLM.1998.1369853803 Search in Google Scholar

[70] Shuai M., Ni Y., Jian X., He S., Zhang J.A.: The level of IL-35 in the circulation of patients with Graves’ disease. Endokrynol. Pol., 2019; 70: 318–322 ShuaiM. NiY. JianX. HeS. ZhangJ.A. The level of IL-35 in the circulation of patients with Graves’ disease Endokrynol. Pol. 2019 70 318 322 10.5603/EP.a2019.001830938833 Search in Google Scholar

[71] Smith T.J., Hegedüs L., Douglas R.S.: Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves’ orbitopathy. Best. Pract. Res. Clin. Endocrinol. Metab., 2012; 26: 291–302 SmithT.J. HegedüsL. DouglasR.S. Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves’ orbitopathy Best. Pract. Res. Clin. Endocrinol. Metab. 2012 26 291 302 10.1016/j.beem.2011.10.002371274722632366 Search in Google Scholar

[72] Stuss M., Michalska-Kasiczak M., Sewerynek E.: The role of selenium in thyroid gland pathophysiology. Endokrynol. Pol., 2017; 68: 440–465 StussM. Michalska-KasiczakM. SewerynekE. The role of selenium in thyroid gland pathophysiology Endokrynol. Pol. 2017 68 440 465 10.5603/EP.2017.005128819948 Search in Google Scholar

[73] Sugawara M., Kita T., Lee E.D., Takamatsu J., Hagen G.A., Kuma K., Medeiros-Neto G.A.: Deficiency of thyroid superoxide dismutase in endemic goiter tissue. J. Clin. Endocrinol. Metab.,1988; 67: 1156– 1161 SugawaraM. KitaT. LeeE.D. TakamatsuJ. HagenG.A. KumaK. Medeiros-NetoG.A. Deficiency of thyroid superoxide dismutase in endemic goiter tissue J. Clin. Endocrinol. Metab. 1988 67 1156 1161 10.1210/jcem-67-6-11563192678 Search in Google Scholar

[74] Świerkot M., Kulawik G., Sarnat-Kucharczyk M., Jagoda K., Mrukwa-Kominek E., Chudek J.: Long-term remission of steroid-resistant Graves’ orbitopathy after administration of anti-thymocyte globulin. Endokrynol. Pol., 2020; 71: 198–199 ŚwierkotM. KulawikG. Sarnat-KucharczykM. JagodaK. Mrukwa-KominekE. ChudekJ. Long-term remission of steroid-resistant Graves’ orbitopathy after administration of anti-thymocyte globulin Endokrynol. Pol. 2020 71 198 199 10.5603/EP.a2019.006732096552 Search in Google Scholar

[75] Tanda M.L., Piantanida E., Liparulo L., Veronesi G., Lai A., Sassi L., Pariani N., Gallo D., Azzolini C., Ferrario M., Bartalena L.: Prevalence and natural history of Graves’ orbitopathy in a large series of patients with newly diagnosed Graves’ hyperthyroidism seen at a single center. J. Clin. Endocrinol. Metab., 2013; 98: 1443–1449 TandaM.L. PiantanidaE. LiparuloL. VeronesiG. LaiA. SassiL. ParianiN. GalloD. AzzoliniC. FerrarioM. BartalenaL. Prevalence and natural history of Graves’ orbitopathy in a large series of patients with newly diagnosed Graves’ hyperthyroidism seen at a single center J. Clin. Endocrinol. Metab. 2013 98 1443 1449 10.1210/jc.2012-387323408569 Search in Google Scholar

[76] Tang X.L., Liu X.J., Sun W.M., Zhao J., Zheng R.L.: Oxidative stress in Graves’ disease patients and antioxidant protection against lymphocytes DNA damage in vitro. Pharmazie, 2005; 60: 696–700 TangX.L. LiuX.J. SunW.M. ZhaoJ. ZhengR.L. Oxidative stress in Graves’ disease patients and antioxidant protection against lymphocytes DNA damage in vitro Pharmazie 2005 60 696 700 Search in Google Scholar

[77] Tsai C.C., Cheng C.Y., Liu C.Y., Kao S.C., Kau H.C., Hsu W.M., Wei Y.H.: Oxidative stress in patients with Graves’ ophthalmopathy: Relationship between oxidative DNA damage and clinical evolution. Eye, 2009; 23: 1725–1730 TsaiC.C. ChengC.Y. LiuC.Y. KaoS.C. KauH.C. HsuW.M. WeiY.H. Oxidative stress in patients with Graves’ ophthalmopathy: Relationship between oxidative DNA damage and clinical evolution Eye 2009 23 1725 1730 10.1038/eye.2008.31018849914 Search in Google Scholar

[78] Tsai C.C., Kao S.C., Cheng C.Y., Kau H.C., Hsu W.M., Lee C.F., Wei Y.H.: Oxidative stress change by systemic corticosteroid treatment among patients having active Graves’ ophthalmopathy. Arch. Ophthalmol., 2007; 125: 1652–1656 TsaiC.C. KaoS.C. ChengC.Y. KauH.C. HsuW.M. LeeC.F. WeiY.H. Oxidative stress change by systemic corticosteroid treatment among patients having active Graves’ ophthalmopathy Arch. Ophthalmol. 2007 125 1652 1656 10.1001/archopht.125.12.165218071117 Search in Google Scholar

[79] Tsai C.C., Wu S.B., Cheng C.Y., Kao S.C., Kau H.C., Chiou S.H., Hsu W.M., Wei Y.H.: Increased oxidative DNA damage, lipid peroxidation and reactive oxygen species in cultured orbital fibroblasts from patients with Graves’ ophthalmopathy: Evidence that oxidative stress has a role in this disorder. Eye, 2010; 24: 1520–1525 TsaiC.C. WuS.B. ChengC.Y. KaoS.C. KauH.C. ChiouS.H. HsuW.M. WeiY.H. Increased oxidative DNA damage, lipid peroxidation and reactive oxygen species in cultured orbital fibroblasts from patients with Graves’ ophthalmopathy: Evidence that oxidative stress has a role in this disorder Eye 2010 24 1520 1525 10.1038/eye.2010.3120300129 Search in Google Scholar

[80] Tsai C.C., Wu S.B., Cheng C.Y., Kao S.C., Kau H.C., Lee S.M., Wei Y.H.: Increased response to oxidative stress challenge in Graves’ ophthalmopathy orbital fibroblasts. Mol. Vis., 2011; 17: 2782–2788 TsaiC.C. WuS.B. ChengC.Y. KaoS.C. KauH.C. LeeS.M. WeiY.H. Increased response to oxidative stress challenge in Graves’ ophthalmopathy orbital fibroblasts Mol. Vis. 2011 17 2782 2788 Search in Google Scholar

[81] Venditti P., Di Meo S.: Thyroid hormone-induced oxidative stress. Cell. Mol. Life Sci., 2006; 63: 414–434 VendittiP. Di MeoS. Thyroid hormone-induced oxidative stress Cell. Mol. Life Sci. 2006 63 414 434 10.1007/s00018-005-5457-916389448 Search in Google Scholar

[82] Veneskoski M., Turunen S.P., Kummu O., Nissinen A., Rannikko S., Levonen A.L., Hörkkö S.: Specific recognition of malondialde-hyde and malondialdehyde acetaldehyde adducts on oxidized LDL and apoptotic cells by complement anaphylatoxin C3a. Free Radic. Biol. Med., 2011; 51: 834–843 VeneskoskiM. TurunenS.P. KummuO. NissinenA. RannikkoS. LevonenA.L. HörkköS. Specific recognition of malondialde-hyde and malondialdehyde acetaldehyde adducts on oxidized LDL and apoptotic cells by complement anaphylatoxin C3a Free Radic. Biol. Med. 2011 51 834 843 10.1016/j.freeradbiomed.2011.05.02921683785 Search in Google Scholar

[83] Von Basedow C.A.: Exophthalmos durch Hypertrophie des Zellgewebes in der Augenhöhle. Wochenschr. für die ges. Heilkunde,1840; 13: 197 Von BasedowC.A. Exophthalmos durch Hypertrophie des Zellgewebes in der Augenhöhle Wochenschr. für die ges. Heilkunde 1840 13 197 Search in Google Scholar

[84] Wall J.R., Lahooti H.: Pathogenesis of thyroid eye disease – does autoimmunity against the TSH receptor explain all cases? Endokrynol. Pol., 2010; 61: 222–227 WallJ.R. LahootiH. Pathogenesis of thyroid eye disease – does autoimmunity against the TSH receptor explain all cases? Endokrynol. Pol. 2010 61 222 227 Search in Google Scholar

[85] Yavuz D.G., Yüksel M., Deyneli O., Ozen Y., Aydin H., Akalin S.: Association of serum paraoxonase activity with insulin sensitivity and oxidative stress in hyperthyroid and TSH-suppressed nodular goitre patients. Clin. Endocrinol., 2004; 61: 515–521 YavuzD.G. YükselM. DeyneliO. OzenY. AydinH. AkalinS. Association of serum paraoxonase activity with insulin sensitivity and oxidative stress in hyperthyroid and TSH-suppressed nodular goitre patients Clin. Endocrinol. 2004 61 515 521 10.1111/j.1365-2265.2004.02123.x15473886 Search in Google Scholar

[86] Yoon J.S., Lee H.J., Chae M.K., Lee S.Y., Lee E.J.: Cigarette smoke extract-induced adipogenesis in Graves’ orbital fibroblasts is inhibited by quercetin via reduction in oxidative stress. J. Endocrinol., 2013; 216: 145–156 YoonJ.S. LeeH.J. ChaeM.K. LeeS.Y. LeeE.J. Cigarette smoke extract-induced adipogenesis in Graves’ orbital fibroblasts is inhibited by quercetin via reduction in oxidative stress J. Endocrinol. 2013 216 145 156 10.1530/JOE-12-025723143154 Search in Google Scholar

[87] Yuksel N., Yaman D., Pasaoglu O.T., Pasaoglu H.: The effect of smoking on mitochondrial biogenesis in patients with Graves’ ophthalmopathy. Ophthalmic. Plast. Reconstr. Surg., 2020; 36: 172–177 YukselN. YamanD. PasaogluO.T. PasaogluH. The effect of smoking on mitochondrial biogenesis in patients with Graves’ ophthalmopathy Ophthalmic. Plast. Reconstr. Surg. 2020 36 172 177 10.1097/IOP.000000000000151431789788 Search in Google Scholar

[88] Zafarullah M., Li W.Q., Sylvester J., Ahmad M.: Molecular mechanisms of N-acetyl-cysteine actions. Cell. Mol. Life Sci., 2003; 60: 6–20 ZafarullahM. LiW.Q. SylvesterJ. AhmadM. Molecular mechanisms of N-acetyl-cysteine actions Cell. Mol. Life Sci. 2003 60 6 20 10.1007/s00018030000112613655 Search in Google Scholar